Research programme - antibody-drug conjugates - Compugen
Latest Information Update: 18 Dec 2013
At a glance
- Originator Compugen
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 12 Dec 2013 Compugen identifies five potential targets for antibody-drug conjugate cancer therapy
- 03 Apr 2013 Early research in Cancer in Israel (unspecified route)